Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

PURPOSE: Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML). PATIENTS AND METHODS: A total of 50...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Cortes, Jorge E., Kim, Dong-Wook, Kantarjian, Hagop M., Brümmendorf, Tim H., Dyagil, Irina, Griskevicius, Laimonas, Malhotra, Hemant, Powell, Christine, Gogat, Karïn, Countouriotis, Athena M., Gambacorti-Passerini, Carlo
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979199/
https://ncbi.nlm.nih.gov/pubmed/22949154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.7522
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados